Survival data for all patients analyzed by tumor EBV status at presentation. (A) Overall survival (OS) was significantly longer (P < .001) for EBV-negative patients (n = 292) than EBV-positive patients (n = 145). (B) Disease-specific survival (DSS) was also significantly longer, in the same cohort, among EBV-negative patients; P = .03. Dotted line indicates EBV-negative; solid line, EBV-positive.